Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2013 4
2014 3
2015 3
2016 4
2017 1
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

15 results
Results by year
Filters applied: . Clear all
Page 1
Human MAP Tau Based Targeted Cytolytic Fusion Proteins.
Akinrinmade OA, Jordaan S, Hristodorov D, Mladenov R, Mungra N, Chetty S, Barth S. Akinrinmade OA, et al. Among authors: hristodorov d. Biomedicines. 2017 Jun 27;5(3):36. doi: 10.3390/biomedicines5030036. Biomedicines. 2017. PMID: 28653985 Free PMC article. Review.
With or without sugar? (A)glycosylation of therapeutic antibodies.
Hristodorov D, Fischer R, Linden L. Hristodorov D, et al. Mol Biotechnol. 2013 Jul;54(3):1056-68. doi: 10.1007/s12033-012-9612-x. Mol Biotechnol. 2013. PMID: 23097175 Review.
Macrophage-targeted therapy: CD64-based immunotoxins for treatment of chronic inflammatory diseases.
Hristodorov D, Mladenov R, Huhn M, Barth S, Thepen T. Hristodorov D, et al. Toxins (Basel). 2012 Sep;4(9):676-94. doi: 10.3390/toxins4090676. Epub 2012 Sep 14. Toxins (Basel). 2012. PMID: 23105975 Free PMC article. Review.
CD64-directed microtubule associated protein tau kills leukemic blasts ex vivo.
Mladenov R, Hristodorov D, Cremer C, Gresch G, Grieger E, Schenke L, Klose D, Amoury M, Woitok M, Jost E, Brümmendorf TH, Fendel R, Fischer R, Stein C, Thepen T, Barth S. Mladenov R, et al. Among authors: hristodorov d. Oncotarget. 2016 Oct 11;7(41):67166-67174. doi: 10.18632/oncotarget.11568. Oncotarget. 2016. PMID: 27564103 Free PMC article.
Targeted killing of rhabdomyosarcoma cells by a MAP-based human cytolytic fusion protein.
Brehm H, Hristodorov D, Pardo A, Mladenov R, Niesen J, Fischer R, Tur MK, Barth S. Brehm H, et al. Among authors: hristodorov d. Cancer Lett. 2015 Sep 1;365(2):149-55. doi: 10.1016/j.canlet.2015.04.004. Epub 2015 Apr 14. Cancer Lett. 2015. PMID: 25888452
Fully human MAP-fusion protein selectively targets and eliminates proliferating CD64(+) M1 macrophages.
Hristodorov D, Mladenov R, Fischer R, Barth S, Thepen T. Hristodorov D, et al. Immunol Cell Biol. 2016 May;94(5):470-8. doi: 10.1038/icb.2016.4. Epub 2016 Jan 8. Immunol Cell Biol. 2016. PMID: 26743033
The Fc-alpha receptor is a new target antigen for immunotherapy of myeloid leukemia.
Mladenov R, Hristodorov D, Cremer C, Hein L, Kreutzer F, Stroisch T, Niesen J, Brehm H, Blume T, Brümmendorf TH, Jost E, Thepen T, Fischer R, Stockmeyer B, Barth S, Stein C. Mladenov R, et al. Among authors: hristodorov d. Int J Cancer. 2015 Dec 1;137(11):2729-38. doi: 10.1002/ijc.29628. Epub 2015 Jun 12. Int J Cancer. 2015. PMID: 26041304 Free article.
EpCAM-selective elimination of carcinoma cells by a novel MAP-based cytolytic fusion protein.
Hristodorov D, Amoury M, Mladenov R, Niesen J, Arens K, Berges N, Hein L, Di Fiore S, Pham AT, Huhn M, Helfrich W, Fischer R, Thepen T, Barth S. Hristodorov D, et al. Mol Cancer Ther. 2014 Sep;13(9):2194-202. doi: 10.1158/1535-7163.MCT-13-0781. Epub 2014 Jun 30. Mol Cancer Ther. 2014. PMID: 24980949 Free article.
Generation and comparative characterization of glycosylated and aglycosylated human IgG1 antibodies.
Hristodorov D, Fischer R, Joerissen H, Müller-Tiemann B, Apeler H, Linden L. Hristodorov D, et al. Mol Biotechnol. 2013 Mar;53(3):326-35. doi: 10.1007/s12033-012-9531-x. Mol Biotechnol. 2013. PMID: 22427250
A novel approach for targeted elimination of CSPG4-positive triple-negative breast cancer cells using a MAP tau-based fusion protein.
Amoury M, Mladenov R, Nachreiner T, Pham AT, Hristodorov D, Di Fiore S, Helfrich W, Pardo A, Fey G, Schwenkert M, Thepen T, Kiessling F, Hussain AF, Fischer R, Kolberg K, Barth S. Amoury M, et al. Among authors: hristodorov d. Int J Cancer. 2016 Aug 15;139(4):916-27. doi: 10.1002/ijc.30119. Epub 2016 Apr 15. Int J Cancer. 2016. PMID: 27037627 Free article.
15 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback